Acer Therapeutics Statistics
Share Statistics
Acer Therapeutics has 0
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | n/a |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 41,270 |
| FTD / Avg. Volume | 1.73% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.42 and the forward
PE ratio is null.
Acer Therapeutics's PEG ratio is
-0.02.
| PE Ratio | -1.42 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | -2.36 |
| P/FCF Ratio | -1.3 |
| PEG Ratio | -0.02 |
Financial Ratio HistoryEnterprise Valuation
Acer Therapeutics has an Enterprise Value (EV) of 49.11M.
| EV / Sales | 0 |
| EV / EBITDA | -2 |
| EV / EBIT | -1.62 |
| EV / FCF | -1.61 |
Financial Position
The company has a current ratio of 0.19,
with a Debt / Equity ratio of -0.7.
| Current Ratio | 0.19 |
| Quick Ratio | 0.19 |
| Debt / Equity | -0.7 |
| Debt / EBITDA | -0.48 |
| Debt / FCF | -0.39 |
| Interest Coverage | -242.67 |
Financial Efficiency
Return on Equity is 166.22% and Return on Invested Capital is 518.32%.
| Return on Equity | 166.22% |
| Return on Assets | -239.68% |
| Return on Invested Capital | 518.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-928,679.03 |
| Employee Count | 30 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1.62M |
| Effective Tax Rate | -6.19% |
Stock Price Statistics
The stock price has increased by -0.02% in the
last 52 weeks. The beta is 0.44, so Acer Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.44 |
| 52-Week Price Change | -0.02% |
| 50-Day Moving Average | 0.81 |
| 200-Day Moving Average | 1 |
| Relative Strength Index (RSI) | 30.16 |
| Average Volume (20 Days) | 2,387,245 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -24.61M |
| Net Income | -27.86M |
| EBITDA | -24.55M |
| EBIT | -26.14M |
| Earnings Per Share (EPS) | -1.77 |
Full Income StatementBalance Sheet
The company has 2.33M in cash and 11.86M in
debt, giving a net cash position of -9.54M.
| Cash & Cash Equivalents | 2.33M |
| Total Debt | 11.86M |
| Net Cash | -9.54M |
| Retained Earnings | -140.75M |
| Total Assets | 14M |
| Working Capital | -55.53M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -30.25M
and capital expenditures -171.17K, giving a free cash flow of -30.42M.
| Operating Cash Flow | -30.25M |
| Capital Expenditures | -171.17K |
| Free Cash Flow | -30.42M |
| FCF Per Share | -1.93 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
